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SUMMARY
In 1967 the first patient in Northern Ireland commenced growth hormone
treatment for short stature. By the end ofDecember 1988 a total of89 patients
hadbeen treated. Thirty-two hadidiopathic isolatedgrowth hormone deficiency,
an incidence of 1-5 new cases per year (in a population of 1-5 million with
approximately 30,000 births per year). Since 1967 the mean age at starting
treatment has fallen from 18 years to 10years and the heightstandard deviation
score has fallen from -4 7 ± 0-6 to -3 4 ± 0-3. The group with classical
growth hormone deficiency (maximum GH < 7mLU/I during insulin-induced
hypoglycaemia) had a greater increase in height velocity over the first year of
treatment, 3-8 ± 0-4 cm, than those with a partial deficiency (maximum
growth hormone 7-1-20 mUl1), 1-9 ± 0-4 cm. All pre-pubertal children
responded with a rise in the height velocity standard deviation score from
-1-8 ± 0-3 before treatment to + 3-5 ± 0-4 over the first year of treatment.
58% ofthe adult males and 25% ofadult females have attained an adult height
within the normal range (3rd centile or above). There have been three deaths,
one each from Fanconi's aplastic anaemia which predated growth hormone
treatment, an accidental fire injury and a relapsing craniopharyngioma. There
have been no deaths from Creutzfeldt-Jakob disease. Growth hormone therapy
is safe and effective, but continues to be commenced late in terms both of age
and height standard deviation score.
INTRODUCTION
The growth promoting activity of crude anterior pituitary extracts in hypo -
physectomized and intact laboratory animals was first demonstrated by Evans
and Long in 1921.1 Isolation and characterization of a relatively pure growth
promoting factor was achieved by Li and his associates in 1945.2 It was a
further decade before a favourable response to human growth hormone (hGH)
treatment was reported by Raben in a 19-year-old male with growth hormone
deficiency.3 In 1967 the first patient in Northern Ireland commenced treatment
with growth hormone for short stature. Over the next 18 years, all growth
hormone used was of human cadaver origin but this was withdrawn in 1985
because of isolated reports from elsewhere of possible contamination with a slow
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virus causing Creutzfeldt-Jakob disease.4 Since then all patients in Northern
Ireland have been treated with growth hormone manufactured by recombinant
DNA technology. Although there are many reports on the improved growth rates
in growth hormone deficient children,5-7 the ultimate success of treatment is the
attainment of a normal adult height. Final heights achieved in patients treated
within the last two decades have been disappointing,8'9' 10 and may reflectthe late
onset of therapy or inadequate doses administered. We have examined the case
records of the 89 patients treated in Northern Ireland from 1967 to 1988 and
report on final height, response rates and practice trends over these 21 years.
METHODS
Laboratory diagnosis: The diagnosis of classical growth hormone deficiency
was made if plasma GH concentration did not exceed 7 mU/I during insulin
hypoglycaemia. Partial growth hormone deficiency was defined as a GH response
of greater than 7 but less than 20 mU/I. 35 patients were diagnosed as growth
hormone deficient after their bone age had reached 10 years. A small number of
this group (13%) excluding those with hypopituitarism or precocious puberty
were not reassessed by either a repeat sex hormone primed stimulation test or by
retesting at cessation of therapy.1'
Anthropometric measurements: Height was measured according to the
recommendations of Tanner and Whitehouse,'2 using a Harpenden stadiometer.
For analysis, the cross sectional standards of Tanner et al were used.'2 Bone age
was determined from X-rays of the left hand and wrist (Tanner et al 13). To
compare growth data at different ages in both sexes, height (and height velocity in
the pre-pubertal group) was expressed as the standard deviation score (SDS)
calculated from the measured height (X), the mean height (X) and the height
standard deviation at that age (SD) according to the formula
SDS = X -x
SD
Height velocity was determined from the difference between two height measure-
ments divided by the time interval between the measurements in decimal years.
Only observed periods of six months or more were used for calculation. Adult
height was predicted at the onset of therapy using the tables of Tanner et al 14
and subsequently compared to the actual achieved adult height in those who
had completed growth. Target heights were calculated using the mid-parental
heights.'5 Comparisons of actual heights with predicted and target heights were
made using paired t-tests. Means ± SEM are reported.
PATIENTS
In the past 21 years, 89 patients have been treated with growth hormone forshort
stature in Northern Ireland. Thirty-two had idiopathic isolated growth hormone
deficiency and one was secondary to cranial irradiation for acute lymphoblastic
leukaemia. Sixteen had partial growth hormone deficiency. Twenty-seven had
panhypopituitarism - 15 idiopathic (of which two presented in infancy with
recurrent hypoglycaemia) and 12 due to known organic pituitary disease (cranio-
pharyngioma, chromophobe adenoma or granulomatous disorders). Ten had
Turner's syndrome, two normal short stature and one spondyloepiphyseal
dysplasia. Ofthose patients with Turner's syndrome, one had in addition classical
growth hormone deficiency, five had partial growth hormone deficiency, and four
had normal growth hormone secretion.
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Fig 1. Number of patients on growth hormone treatment per year and the number of new cases
diagnosed each year in Northern Ireland, 1967-1988.
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Fig 2. Mean age and height standard deviation score (SDS) when growth hormone treatment first
commenced (1967-1988)
The Ulster Medical Society, 1989.
156
20 -
15-
10 -
5-
0-
0-
-1-
-2
-3-
-4-
-6-
I
iGrowth hormone therapy
The numbers of patients on treatment and the numbers of new patients
commenced on treatment each year, including those with a diagnosis of classical
idiopathic growth hormone deficiency has risen with time (Fig 1). The mean age
at onset of therapy has fallen from 18 years in 1967 to 10 years in 1988 and the
mean height SDS at commencement of therapy has also fallen with time (Fig 2).
Five cases had a bone age in advance of their chronological age at the onset of
therapy, ofwhom four had received cranial irradiation which has been reported to
be associated with the premature onset of puberty.16 The mean delay in bone age
in the rest of the group with growth hormone deficiency at commencement of
therapy was -2 8 ±0-2 years.
There have been three deaths in the group, one each from an accidental fire
injury, Fanconi's aplastic anaemia which predated growth hormone therapy and
from a relapse of a craniopharyngioma. There were no deaths from Creutzfeldt-
Jakob disease.
RESULTS
In 22 patients (25 %) assessment of the response to growth hormone treatment
was not possible, as there was either no pre-treatment assessment of growth
velocity (9 patients) due to the late age of diagnosis (15 2 - 18 9 years), or
because the duration of therapy was less than six months (13 patients). In the
remaining 67 patients, 41 (61 %) responded with an acceleration in growth
velocity of greater than 2-0 cm/year in the first year of treatment (range
2 -0 - 10*6 cm/yr), 19 (29%) showed an acceleration of less than 2 *0 cm/year,
and 7 (10%) showed no response to treatment (3 panhypopituitarism, one idio-
pathic growth hormone deficiency, one normal short stature and two with
Turner's syndrome. The group with classical growth hormone deficiency had a
greater increase in height velocity than those with partial growth deficiency
(3Q8 ± 0 4 vs 1-9 ± 0 4 cm/yr). All patients with growth hormone deficiency
in the pre -pubertal group responded with a rise in height velocity SDS, which
was -1 *8 ± 0 3 before treatment and + 3 5 ± 0 4 after treatment. There was
a significant negative correlation between the change in height velocity SDS after
the first year of growth hormone treatment and the growth hormone response
to insulin -induced hypoglycaemia in this pre -pubertal group (r = -0-42,
p <0*05; n = 25) (Fig 3). The ratio of change in bone age to chronological
age (ABA/ ACA) up to a bone age of 12 years in girls and 14 years in boys
was 1-1 ± 0 06.
Twenty-nine patients had completed therapy and an adult height has been
recorded in 19 males and 8 females. The mean adult height for males was
162 -4 ± 0 9 cm and for females 147-4 ± 2
-8 cm; these were not significantly
different from the mean predicted adult height (actual height 159 ± 1 .4 cm vs
predicted height 158 ± 1 *7 cm). However, they were significantly lower than the
target height (males 162-4 ± 0*9 cm vs 170 8 ± 0 9 cm, p <0 001; females
147-4 ± 2-2 cmvsT56-6 ± 20cm, p<0 05).
DISCUSSION
It has been postulated that growth becomes growth hormone dependent after
birth.'7 A highly significant correlation between height and spontaneous growth
hormone secretion has been described in pre-pubertal children.'8 Our findings
of 100% response rates in the pre-pubertal group, and the significant negative
correlation between the change in height velocity standard deviation score over
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Fig 3. The change in height velocity standard deviation score (SDS) over the first treatment year
related to the GH response to insulin induced hypoglycaemic stimulation in the pre-pubertal group
with growth hormone deficiency (n = 25). One boy with normal short stature has been excluded.
r = -0-42, p < 005.
the first yearoftreatment and growth hormone secretion in this group would be in
accordance. A non-linear relationship between growth hormone secretion and
height has been described in the pubertal ages.'8 Sex hormones account for
pubertal growth acceleration which can occur in the presence ofvery little growth
hormone.'9 Patients with Laron-type short stature, who have an end organ
resistance to the action of growth hormone, can have a normal pubertal growth
spurt.20
A recentstudy comparing final heightsofchildren treated before and after growth
hormone became available found no significant difference between the final
heights of those patients with multiple hormone deficiencies treated with growth
hormone and androgens, and those treated with androgens alone.'9 Growth
hormone succeeded in achieving an adult height approximately 3-4 years earlier,
suggesting that fusion of the epiphysis occurred earlier in the GH treated group.
All but one of the patients in the growth hormone treated group had been
pubertal at onset of therapy.
Our findings offinal heights 2 -0 SD below the normal population mean for males
and 3-0 SD below for females are in accordance with others.8-0 The failure to
reach target heights based on mid-parental heights suggests that the patients
failed to reach their true genetic potential for growth. It has been postulated that
© The Ulster Medical Society, 1989.
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growth hormone therapy in growth hormone deficient children prevents further
"loss" of height potential but may not succeed in regaining lost height.21 The
disappointing final heights may reflect the late age of diagnoses and greater 'lost'
height at diagnoses. All ofthe patients who have reached adult height in Northern
Ireland were treated with a standard dose regimen three times a week. Optimum
doses are now being worked out based on body weight and given by daily
subcutaneous injection with improved growth rates.22'23
As growth has been shown to be growth hormone dependent in the pre-pubertal
years, (when the ratio of bone age to chronological age does not advance at a
figure greater than 1 -0) treatment of the growth hormone deficient child early in
this period of growth should allow greater potential for normal growth and
improved final height. We would recommend that height measurements should
be plotted on a height centile chart. A height falling three standard.deviations
below the mean for age on a single measurement, or a height velocity over a full
year below the 25th centile, should be referred for further evaluation. A random
sample of growth hormone is of little value; a serum sample greater than 20
mU/I following exercise or sleep excludes growth hormone deficiency. If the
growth hormone level is below 20 mU/I, growth hormone deficiency is possible,
and the child should be investigated further.
Endocrinological evaluation will vary depending on the child's bone age; at
a bone age of greater than 10 years, a sex hormone primed insulin-induced
hypoglycaemic stimulation test should be carried out. A growth hormone
response of less than 7 mU/I to insulin stimulation indicates classical growth
hormone deficiency. A response of between 7-1 and 20 mU/I suggests partial
growth hormone deficiency. However, the stimulation test should be repeated in
such cases.
The trend in Northern Ireland over the last 21 years reflects an earlier age at
diagnosis and a fall in the height deficit at onset of therapy. However, the mean
age at diagnosis in 1988 was still at the end of the pre-pubertal growth phase,
when a large height deficit has already occurred. If the final height prognosis is to
improve, children with short stature should be identified earlier, ideally before
school age. With the improved availability of treatment and the establishment of
optimum treatment regimens, the height prognosis for children in the next two
decades should improve.
We are grateful to many colleagues who have referred patients because ofshort stature over the years
of this study. The Growth Clinics at the Royal Victoria Hospital and the Royal Belfast Hospital for Sick
Children continue to assess and supervise the management of children and adults requiring growth
hormone therapy.
REFERENCES
1. Evans HM, Long JA. The effects of anterior lobe administered intraperitoneally upon growth
maturity and oestrous cycles of the rat. Anat Rec 1921; 21: 62-3.
2. Li CH. Growth and adrenocorticotrophic hormones of the anterior pituitary. Harvey Lectures
1950-51; 46: 181.217.
3. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab
1958; 18: 901.3.
4. Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease
from human growth hormone therapy. N Engl J Med 1985; 313: 728-31.
© The Ulster Medical Society, 1989.160 The Ulster Medical Journal
5. Tanner JM, Whitehouse RH, Hughes PCR, Vince FP. Effect of human growth hormone
treatment for 1 to 7 years on growth of 100 children with growth hormone deficiency, low birth-
weight, inherited smallness, Turner's syndrome and other complaints. Arch Dis Child 1971; 46:
745-82.
6. Aceto T Jr, Frasier SD, Hayles AB, Meyer-Bahlburg HSL, Parker ML, Dichiro JJ. Collaborative
study of the effects of human growth hormone in growth hormone deficiency. 1. First year of
therapy. J Clin Endocrinol Metab 1972; 35: 483-96.
7. Milner RDG, Fraser TR, Brook CGD. Experience with human growth hormone in Great Britain:
the report of the MRC Working Party. Clin Endocrinol 1979; 1 1: 15-38.
8. Burns EC, Tanner JM, Preece MA, Cameron N. Final height and pubertal development in 55
children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with
human growth hormone. Eur J Pediatr 1981; 137: 155.64.
9. Joss E, Zuppinger K, Schwarz HP, Roten H. Final height of patients with pituitary growth failure
and changes in growth variables after long term hormonal therapy. Pediatr Res 1983; 17:
676-9.
10. Lenko HL, Leisti S, Perheentupa J. The efficacy of growth hormone in different types of growth
failure: an analysis of 101 cases. Eur J Pediatr 1982; 138: 241.9.
11. Milner RDG, Burns EC. Investigation of suspected growth hormone deficiency. Arch Dis Child
1982; 57: 944-7.
12. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight,
height velocity and weight velocity: British children, 1-965. Arch Dis Child 1966; 41: 613-35.
13. Tanner JM, Whitehouse RH, Healy MJ. A new system for estimating skeletal maturity from the
hand and wrist with standards derived from a study of 2600 healthy British children. Centre
International de L'Enfance Paris. 1962.
14. Tanner JM, Whitehouse RH, Marshall WA, Healy MJ, Goldstein H. Assessment of skeletal
maturity and prediction of adult height (TW2 method). London, New York, San Francisco:
Aca'demic Press, 1975.
15. Tanner JM, Goldstein H, Whitehouse RH. Standards for children's heights at ages 2 -9 years
allowing for height of parents. Arch Dis Child 1970; 45: 755-62.
16. LeiperAD, Stanhope R, Kitching P, Chessells JM. Precocious and premature puberty associated
with treatment of acute lymphoblastic leukaemia. Arch Dis Child 1987; 62: 1107-12.
17. KarlbergJ, Albertsson-Wikland K. Infancy growth pattern related togrowth hormone deficiency.
Acta Paediatr Scand 1988; 77: 385-91.
18. Albertsson-Wikland K, Rosberg S. Analysis of 24-hour growth hormone profiles in children:
relation to growth. J Clin Endocrinol Metab 1988; 67: 493-500.
19. van der Werff ten Bosch JJ, Bot A. Does hGH treatment promote adult height of hypopituitary
children? Netherlands J Med 1988; 32: 217-25.
20. Laron Z, Raanana S, Pertzelan A. Puberty in Laron-type dwarfism. Eur.J Pediatr 1980; 134:
79-83.
21. Bundak R, Hindmarsh PC, Smith PJ, Brook CGD. Long-term auxologic effects of human
growth hormone. J Pediatr 1988; 112: 875-9.
22. Smith PJ, Hindmarsh PC, Brook CGD. Contribution of dose and frequency of administration to
the therapeutic effect of growth hormone. Arch Dis Child 1988; 63: 491-4.
23. Gertner JM, Tamborlane WV, Gianfredi SP, Genel M. Renewed catch -up growth with increased
replacement doses of human growth hormone. J Pediatr 1987; 110: 425-8.
© The Ulster Medical Society, 1989.